Due to in­creas­ing com­pe­ti­tion, Gala­pa­gos’ CAR-T ex­its au­toim­mune dis­eases

Gala­pa­gos has stopped de­vel­op­ing its CD19 CAR-T can­di­date in au­toim­mune dis­eases, in­clud­ing plans for a tri­al in sys­temic lu­pus ery­the­mato­sus, mark­ing the first no­table ex­it …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER